Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes

Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes

Mirko V Sikirica,1 Alan A Martin,2 Robert Wood,3 Andrea Leith,3 James Piercy,3 Victoria Higgins3 1Value Evidence and Outcomes, GlaxoSmithKline, Collegeville, PA, USA; 2Value Evidence and Outcomes, GlaxoSmithKline, London, UK; 3Diabetes, Adelphi Real World, Bollington, Cheshire, UK Aim: Nonadherence...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Sikirica MV, Martin AA, Wood R, Leith A, Piercy J, Higgins V
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2017
Materias:
antidiabetic drug
cross-sectional survey
discontinuation
incretins
incretin therapy
glycemic control
Specialties of internal medicine
RC581-951
Acceso en línea:https://doaj.org/article/202a3453a4724bdbaf304549fd75661f
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/202a3453a4724bdbaf304549fd75661f

Ejemplares similares